NEFL and Alzheimer disease: NfL levels have been suggested as a promising biomarker to discriminate cognitive decline due to AD in its prodromal or preclinical stages [25, 26], even if the validity of their discriminatory power has not been determined for levels of this biomarker obtained from blood [27].